| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.00 [0.73, 1.37] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.25 [0.94, 1.66] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 1.24 [0.24, 6.50] | | > 1 | | 0% | 1 study (1/-) | 59.8 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.52 [0.42, 5.53] | | < 1 | | 0% | 1 study (1/-) | 26.4 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.15 [0.67, 1.97] | | < 1 | | 0% | 1 study (1/-) | 30.3 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.12 [0.21, 5.90] | | < 1 | | 0% | 1 study (1/-) | 44.7 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.72 [1.15, 6.39] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 2.26 [1.24, 4.14] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 2.73 [1.26, 5.89] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.74 [0.19, 2.79] | | < 1 | | 0% | 1 study (1/-) | 67.3 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.85 [0.50, 1.44] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Dyspnoea TRAE (grade 3-4) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.81 [0.20, 16.42] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 0.29 [0.05, 1.77] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 2.31 [0.49, 10.78] | | < 1 | | 0% | 1 study (1/-) | 14.5 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 3.22 [0.39, 26.58] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.44 [0.06, 3.19] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
| Dermatitis acneiform AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.89 [0.68, 5.22] | | < 1 | | 0% | 1 study (1/-) | 11.1 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.49 [0.17, 1.40] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.08 [0.02, 0.37] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Intestinal perforation AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.02 [0.00, 0.39] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 6.47 [0.36, 115.44] | | < 1 | | 0% | 1 study (1/-) | 10.4 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 1.59 [0.32, 7.82] | | < 1 | | 0% | 1 study (1/-) | 28.6 % | NA | not evaluable | | non important | - |
| Rash maculopapular AE (grade 3-4) | 0.44 [0.03, 7.19] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 0.44 [0.06, 3.19] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
